Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 34Dermatologic 11Head & Neck 9Thoracic 8Breast 7Genitourinary 6Gastrointestinal 6Gynecologic 5Sarcoma 4

Conditions

Sarcoma 43Melanoma 19Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Glioblastoma 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Gliosarcoma 7Lung Neoplasms 6Histiocytoma, Malignant Fibrous 6Carcinoma, Renal Cell 6Osteosarcoma 5Liposarcoma 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Sarcoma, Synovial 4Sarcoma, Kaposi 4Neurofibrosarcoma 4Lymphoma 4Hemangiosarcoma 4Carcinoma, Merkel Cell 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Recurrence 3

Interventions

Cyclophosphamide 58Filgrastim 37Radiotherapy 31Busulfan 28fludarabine phosphate 26Antilymphocyte Serum 25Cyclosporine 24Peripheral Blood Stem Cell Transplantation 23Etoposide 22Methotrexate 20Melphalan 18Mycophenolic Acid 17Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Vincristine 13Cytarabine 13Tacrolimus 12Rituximab 11Whole-Body Irradiation 9Thiotepa 9Prednisone 9Doxorubicin 8Leucovorin 7sargramostim 6aldesleukin 6Granulocyte Colony-Stimulating Factor 6Psychiatric Rehabilitation 5Daunorubicin 5pembrolizumab 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma × pembrolizumab × Sarcoma × Clear all
NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Presage Biosciences

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT03349450 2026-05-06

SPiReL

Sunnybrook Health Sciences Centre

Phase 2 Completed
25 enrolled 18 charts
LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡